Medtronic (MDT) Misses Q4 EPS by 5c, Offers Guidance
Get Alerts MDT Hot Sheet
Price: $87.15 +0.26%
Revenue Growth %: -0.6%
Financial Fact:
Earnings before income taxes: 1.19B
Today's EPS Names:
FSI, RELV, NEOM, More
Revenue Growth %: -0.6%
Financial Fact:
Earnings before income taxes: 1.19B
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Medtronic (NYSE: MDT) reported Q4 EPS of $1.52, $0.05 worse than the analyst estimate of $1.57. Revenue for the quarter came in at $8.09 billion versus the consensus estimate of $8.44 billion.
GUIDANCE:
Medtronic sees FY2023 EPS of $5.53-$5.65, versus the consensus of $5.66.
- The company today issued its fiscal year 2023 revenue growth and EPS guidance.
- The company expects organic revenue growth in its fiscal year 2023 in the range of 4% to 5%. If recent foreign currency exchange rates hold, fiscal year 2023 revenue would be negatively affected by approximately $1.0 billion to $1.1 billion.
- The company expects fiscal year 2023 non-GAAP EPS in the range of $5.53 to $5.65, including an estimated 20 to 25 cent negative impact from foreign currency translation based on recent foreign currency exchange rates.
- "We expect recent and upcoming product launches to make a difference across our businesses this coming fiscal year," said Karen Parkhill, Medtronic chief financial officer. "Supply chain, inflation, and foreign exchange are expected to create near-term pressure. Yet, we remain focused on driving our R&D investments to accelerate our growth and create large, long-term returns for our shareholders."
For earnings history and earnings-related data on Medtronic (MDT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Oxford Industries (OXM) Reports In-Line Q4 EPS, provides guidance
- Pulse Biosciences, Inc. (PLSE) Tops Q4 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!